Amylyx Pharmaceuticals Inc News - AMLX | ADVFN

Register to chat with like-minded investors on our interactive forums.

Get Started

Home
Investing
Stocks
USA
NASDAQ
Amylyx Pharmaceuticals Inc (AMLX)
Amylyx Pharmaceuticals Inc (AMLX) News

Amylyx Pharmaceuticals Inc (AMLX)

1.88

-0.07

(-3.59%)

Closed April 25 4:00PM

Delayed by 15 minutes

1.87

-0.01

(-0.53%)

After Hours: 7:31PM

Delayed by 15 minutes

Get an advanced news scanner tailored to your needs by ADVFN

Enhance your trading experience

Amylyx Pharmaceuticals Announces Interim Data From Ongoing Phase 2 HELIOS Clinical Trial Demonstrating Improvements in Pancreatic Function and Glycemic Control with AMX0035 in People with Wolfram Syndrome

- Interim analysis, including eight participants assessed at Week 24, demonstrated improvements in pancreatic function and glycemic control, as...

The Gross Law Firm Notifies Amylyx Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - AMLX

The Gross Law Firm Notifies Amylyx Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming...

Amylyx Pharmaceuticals to Host Virtual Webcast to Discuss Interim Data from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on April 10, 2024

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced the Company will host a virtual webcast with management...

Amylyx Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - AMLX

Amylyx Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm...

Amylyx Pharmaceuticals Announces Formal Intention to Remove RELYVRIO®/ALBRIOZA™ from the Market; Provides Updates on Access to Therapy, Pipeline, Corporate Restructuring, and Strategy

- Based on topline results from the Phase 3 PHOENIX trial of AMX0035 in ALS, Amylyx has started a process with the FDA and Health Canada of...

The Gross Law Firm Reminds Amylyx Pharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 9, 2024 - AMLX

The Gross Law Firm Reminds Amylyx Pharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit with a...

The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Amylyx Pharmaceuticals, Inc.(AMLX) Shareholders

The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Amylyx Pharmaceuticals...

Shareholders of Amylyx Pharmaceuticals, Inc. Should Contact The Gross Law Firm Before April 9, 2024 to Discuss Your Rights - AMLX

Shareholders of Amylyx Pharmaceuticals, Inc. Should Contact The Gross Law Firm Before April 9, 2024 to Discuss...

INVESTOR ALERT: AMYLYX PHARMACEUTICALS, INC. (NASDAQ: AMLX) INVESTORS WITH LOSSES OF MORE THAN $100,000 ENCOURAGED TO SEEK APPOINTMENT AS LEAD PLAINTIFF - April 9, 2024 DEADLINE

INVESTOR ALERT: AMYLYX PHARMACEUTICALS, INC. (NASDAQ: AMLX) INVESTORS WITH LOSSES OF MORE THAN $100,000...

The Gross Law Firm Notifies Shareholders of Amylyx Pharmaceuticals, Inc.(AMLX) of a Class Action Lawsuit and an Upcoming Deadline

The Gross Law Firm Notifies Shareholders of Amylyx Pharmaceuticals, Inc.(AMLX) of a Class Action Lawsuit and...

Amylyx Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before April 9, 2024 to Discuss Your Rights - AMLX

Amylyx Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before April 9...

Amylyx Pharmaceuticals Appoints Bernhardt Zeiher, MD, FCCP, FACP, to its Board of Directors

- Dr. Zeiher brings more than 20 years of drug development experience in areas with serious unmet treatment needs at companies including Astellas...

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 9, 2024 in Amylyx Lawsuit - AMLX

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 9, 2024 in Amylyx Lawsuit...

Form SC 13G - Statement of acquisition of beneficial ownership by individuals

Amylyx Pharmaceuticals, Inc. Class Action: The Gross Law Firm Reminds Amylyx Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 9, 2024 - AMLX

Amylyx Pharmaceuticals, Inc. Class Action: The Gross Law Firm Reminds Amylyx Investors of the Pending Class...

1
Next

ALS/MND TREATOR

ALS/MND TREATOR 2 weeks ago

We haven't been contacted by Amylyx

Scarface

Scarface 2 weeks ago

There’s a rumor Amylyx is looking at a private company PHA LLC. They own a worldwide ALS Treatment covered by a National Institute of Health Paper and others. I found their information by doing an Internet search of, ALS/JIWULI and all the information came. It’s just a rumor but it would make sense

willlbone

willlbone 3 weeks ago

So several employees sold shares day before bad news released. Insider trading is illegal.

scooby5

scooby5 3 weeks ago

Since the company is pulling the ALS drug and laying off 70% of the workforce, does the company have any other profitable drugs? How much of their revenue came from the ALS drug?

maent

maent 3 weeks ago

They did have income from the drug in question. If they do not make them pull it, then yes, this is a no brainer.

scooby5

scooby5 3 weeks ago

It looks like the company has .70 in earnings and a PE in the 4’s. Were the earnings affected by the bad news on the drug trials? Seems like a no brainer to buy here if the earnings stay in the same range.

maent

maent 4 weeks ago

Yes sir. I loaded $4 Jan25 calls.we will see how it plays out. I still haven't heard anything about them pulling the drug off the market. It does help. I'm sure we will hear something either way soon.

Monksdream

Monksdream 4 weeks ago

maent

maent 1 month ago

Seems to be settling in around the $3.15 area. Slowly loading this for a swing.

jmgreeny

jmgreeny 1 month ago

All the stock give away in Jan to execs really primed the share holders to buy more.

maent

maent 1 month ago

I will be very patient with this one. We await news of drug being pulled from the shelves or there is a very good chance they leave it and just change the label. If they allow it to stay on the market, this runs hard!

GO4AWILDRIDE

GO4AWILDRIDE 1 month ago

maent

Nice second day cat bounce.

Looking for a higher plateau in the next few days.

GLTU

GO4AWILDRIDE

maent

maent 1 month ago

Nice gap that needs to be filled.

maent

maent 1 month ago

Volume is ramping up steadily since noon. Nice SC-13G 4.2 Million shares.

maent

maent 2 months ago

I could see this getting back to $7-10 by the end of next week.

CEO_BC

CEO_BC 2 months ago

$AMLX

Relyvrio treatment a year costs 159K$ per patient. There are 100K patient in US in need for such drug treatment. We did 110M revenue in last quarter reported at 40K$ drug costs which make it to 3K patient… from a market size of 100K (3% adoption)

The market competition for ALS is way higher than for Wolframe Syndrome.

Wolframe Syndrome has 25K patient market size in US and 25K patient in Europe. Europe has a strong need to a better drug for it. There is a strong potential that we reach quick 500M-1B$ revenue a year in the Wolframe Syndrom drugs Market.

I would assume that the company will share soon a market potential and forecast for the treatment of Wolframe Syndrome.

We were at $12 SP before we sold anything. The potential here is still way higher than $12. The larger strategic investors know this too. Expect that some will increase further holding at this price level.

CEO_BC

CEO_BC 2 months ago

$AMLX

- pipeline below
-Book Value Per Share: 6.40
-Total Cash Per Share: 5.48
-Net Cash/Share 5.42
-Next catalyst: AMX0035 - (HELIOS)
Wolfram Syndrome: Phase 2 first patient dosed April 13, 2023. Phase 2 enrollment completed, noted February 8, 2024.Phase 2 data due in 2H 2024.

realtmg

realtmg 2 months ago

Took a position

ErnieBilco

ErnieBilco 2 months ago

That's music to me ears. It was absolutely destroyed today.

maent

maent 2 months ago

I flipped it a few times today. I ended up holding 2600 shares for the weekend. This is too good a company. .73 EPS is not a $3 company.

DD14

DD14 2 months ago

262 employees and 400 million in revenue in 2023, that’s why I’m taking advantage on this one drug refusal : )))) they have 5 million in cash and revenues.

DD14

DD14 2 months ago

I’m loading heavy

DD14

DD14 2 months ago

They have many other products, that’s why the market cap was 1.3 billion.

girlfriend

girlfriend 2 months ago

They failed the phase3 for the Phoenix trial and are now going to huddle to see what the next steps are. That's bad news.

I didn't expect the shares to break down as much as they have but I have been a buyer today in the 2.90's up to 3.30.

Best of luck to all they have a rather clean balance sheet.

GO4AWILDRIDE

GO4AWILDRIDE 2 months ago

DD14

I hope you are correct, I read the the news release and did not see anything that would make investors drop this stock as much as they did.
I hope to ride this up back to $15-18 or more.

GLTU

GO4AWILDRIDE

DD14

DD14 2 months ago

Watch out, next Monday this will be over $10

ErnieBilco

ErnieBilco 2 months ago

Been nibbling this morning gotta be something if the price targets are maintained in the $30s

Awl416

Awl416 2 months ago

Amylyx Pharmaceuticals Announces Topline Results From Global Phase 3 PHOENIX Trial of AMX0035 in ALS

jmgreeny

jmgreeny 2 months ago

Well their core business saved the shipped?

Scarface

Scarface 2 months ago

I’ve been told, PHA signed some sort of agreement with BLUE POPPY last week. I can’t find a ticker for BLUE POPPY. I researched BLUEPOPPY.COM
They are for real. The ticker? for the reverse merger? I smell money

Scarface

Scarface 2 months ago

A guy? Went on twitter last night and challenged a tweet from AMYLYX. I’m telling you this is a big problem for AMYLYX.

NASDAQ2020

NASDAQ2020 2 months ago

Have someone with Ihub subscription search for chatter on the subject

Keep an eye on Twitter too

Scarface

Scarface 2 months ago

https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2022.990802/full

This is a fact. Read the attached article to the link above. The company behind it is PHA LLC. They own JiWuLiProducts.com
Holders of all Trademarks Intellectual Property for JiWuLi Products in the United States and the European Union. And as of now the only compounder in the world for this treatment. Now what Amylax doesn’t want anyone to know. Ji Wu Li treatment has better results than Relyvrio. Ji Wu Li treatment costs around $1000.00 per month compared to Relyvrio at $12,000. per month. I know PHA is looking at several tickers to do a reverse merger. That ticker will make people a lot of money! Help me

Scarface

Scarface 2 months ago

Amylyx is worried about a company, PHA LLC, trademark holders and intellectual property holder in the United States and the European Union for the Motor Neuron/ALS/LOU GERIG DISEASE. For the Ji Wu Li treatment, beginning in January started shipping Worldwide along with signing significant supply contracts with Neurologists around the world. I was told they were involved with the National Institute of Health published paper, Dr. Sven Schroder from Hamburg, Germany on how Ji Wu Li treatment has better results than Relyvrio at a max treatment cost of $1000.00 per month compared to $12,000.00 per month for Relyvrio. Here’s kicker, PHA are looking at several reverse merger targets. If knew the target, there’s money to be made!

jmgreeny

jmgreeny 3 months ago

I can’t believe nobody has been on this page for a long time

So is AMLX broken or just going thru a reboot? Any ideas or opinions or facts someone can put out there

jmgreeny

jmgreeny 3 months ago

So does anybody have an opinion on this stock it’s been a while since any posying

jmgreeny

jmgreeny 6 months ago

Is this company broken. Or should we just wait. Any suggestions

jmgreeny

jmgreeny 7 months ago

So price of Amlx 23-24 price target 50 by financial analyst. Steady slide lower to 18.

Any news on why

conix

conix 2 years ago

Another viewpoint on the ALS drug

https://www.medpagetoday.com/opinion/second-opinions/101206?xid=nl_secondopinion_2022-10-16&eun=g350924d0r

MiamiGent

MiamiGent 2 years ago

Ya Max, I see it kicking up it hoffs, want'n to go.
I have one share as a bookmark. Look'n to pounce on any dip
Have already banked nicely on this

https://stockcharts.com/h-sc/ui?s=AMLX

Max77

Max77 2 years ago

Notice the cup and handle formation- super bullish chart pattern

MiamiGent

MiamiGent 2 years ago

.
AMLX Amylyx Pharmaceuticals Receives FDA Approval Of Relyvrio For Treatment Of Amyotrophic Lateral Sclerosis
By Benzinga — 4:38 PM ET 09/29/22

MiamiGent

MiamiGent 2 years ago

AMLX The Motley Fool
Sun, September 25, 2022 at 9:23 AM

AMLX Three Motley Fool contributors have joined this roundtable to scour the market for some exciting initial public offerings (IPOs) in the healthcare field. Alex Carchidi (Amylyx Pharmaceuticals): Amylyx is worth owning because there's a solid chance it'll soon commercialize the first treatment for amyotrophic lateral sclerosis (ALS) that prolongs survival time while also slowing the disease's progression. Its medicine, AMX0035, has been approved for sale in Canada since late July, and regulators at the U.S. Food and Drug Administration will weigh in on the company's application for commercialization on Sept. 29.This biotech is ready for blastoff
It's also in the final stages of preparing to launch the drug in the European Union, pending the green light from regulators, which could come in the first half of 2023.

Since its IPO in early January of this year, its shares are up by nearly 61.6%, and it'll likely rise even higher. Right now, its revenue is negligible, as there hasn't been an earnings report since the approval of its drug in Canada. But next year, analysts estimate on average that it'll bring in around $174 million if AMX0035 launches in the U.S. as planned, and that'll mean the company's top revenue growth rate should accelerate dramatically.

NASDAQ: AMLX
Amylyx Pharmaceuticals, Inc.
Today's Change
(+3.23%) $0.91
Current Price
$29.09
KEY DATA POINTS
Market Cap
$2B
Day's Range
$27.95 - $29.45
52wk Range
$6.51 - $33.41
Volume
515,343
Avg Vol
1,572,472
Gross Margin
-20475.44%
Dividend Yield
N/A

Furthermore, there aren't any other ALS medicines, so Amylyx will have free rein of the global market, and that could power shareholder returns for years. And, as it already has its foot in the door thanks to its approval in Canada, it isn't as risky as other biotech stocks, though it's still not exactly a great pick for investors with a low risk tolerance.

MiamiGent

MiamiGent 2 years ago

MiamiGent

Member Level
Re: None

Friday, September 09, 2022 3:32:12 PM

Post#
622407 of 622435

AMLX I just got in at 29.80
Received recommendation of FDA Independant Advisory Committee yesterday
Up 60+% between yesterday and today.
I'm counting on "the three day rule" and publicity over weekend to send it higher Monday
A drug for ALS where there is little to offer sufferers now
https://stockcharts.com/h-sc/ui?s=AMLX

sorkin

sorkin 2 years ago

Bought $30 puts

sorkin

sorkin 2 years ago

Sold my $30 calls

subslover

subslover 2 years ago

And the run continues :))))))))))))))))))))))0

subslover

subslover 2 years ago

Oh, ok. I think it's phenomenal. AMLX

sorkin

sorkin 2 years ago

Will SRPT buy AMLX?

sorkin

sorkin 2 years ago

Hope you are not right

Amylyx Pharmaceuticals

Delayed Upgrade Clock

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions